drugset / Trial / NCT02707497
The Effect of REcombinant Human Thrombopoietin (rhTPO) on Sepsis Patients With aCUte Severe thrombocytopEnia
Phase 2/3
Unknown
200 enrolled
Ruilan Wang
Changhai Hospital · collabFudan University · collabHuadong Hospital · collabSecond Affiliated Hospital of Nanchang University · collabShanghai Jiao Tong University School of Medicine · collabShanghai Tongji Hospital, Tongji University School of Medicine · collabShanghai University of Traditional Chinese Medicine · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether recombinant human thrombopoietin(rhTPO) can rapidly increase the platelets counts, shorten the time of the platelet returned to normal, reduce platelet transfusion and bleeding events, prompt recovery of organ function, decrease the length of ICU stay, and eventually reduce the 28-day mortality in sepsis patients with severe thrombocytopenia.
Timeline
- Start
- 2019-04-01
- Primary completion
- 2024-08-31
- Completion
- 2024-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | recombinant human thrombopoietin | Protein / enzyme biologic | 15000 iu | Subcutaneous |